ANAPTYSBIO, INC. Debt Securities, Available-for-sale, Noncurrent
ANAPTYSBIO, INC. (ANAB) had Debt Securities, Available-for-sale, Noncurrent of $0 as of 2026-06-30, per its 10-KT filed 2026-09-21.
Financial Statements › Balance Sheet › Assets › Assets, Noncurrent
us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent · last filed 2026-09-21
- 2026-06-30: Debt Securities, Available-for-sale, Noncurrent $0.00.
- 2025-12-31: Debt Securities, Available-for-sale, Noncurrent $0.00.
- 2025-09-30: Debt Securities, Available-for-sale, Noncurrent $7.70M.
- 2025-06-30: Debt Securities, Available-for-sale, Noncurrent $28.00M.
| Period end | Debt Securities, Available-for-sale, Noncurrent |
|---|---|
| 2026-06-30 | $0.00 10-KT · filed 2026-09-21 |
| 2025-12-31 | $0.00 10-KT · filed 2026-09-21 |
| 2025-09-30 | $7.70M 10-Q · filed 2025-11-04 |
| 2025-06-30 | $28.00M 10-Q · filed 2025-08-06 |
| 2025-03-31 | $43.02M 10-Q · filed 2025-05-05 |
| 2024-12-31 | $35.47M 10-KT · filed 2026-09-21 |
| 2024-09-30 | $27.91M 10-Q · filed 2024-11-05 |
| 2024-06-30 | $42.65M 10-Q · filed 2024-08-05 |
| 2024-03-31 | $15.47M 10-Q · filed 2024-05-09 |
| 2023-12-31 | $27.03M 10-K · filed 2025-02-27 |
| 2023-09-30 | $40.20M 10-Q · filed 2023-11-02 |
| 2023-06-30 | $59.24M 10-Q · filed 2023-08-07 |
| 2023-03-31 | $94.93M 10-Q · filed 2023-05-11 |
| 2022-12-31 | $142.94M 10-K · filed 2024-03-11 |
| 2022-09-30 | $147.51M 10-Q · filed 2022-11-08 |
| 2022-06-30 | $129.99M 10-Q · filed 2022-08-08 |
| 2022-03-31 | $91.19M 10-Q · filed 2022-05-04 |
| 2021-12-31 | $67.10M 10-K · filed 2023-03-01 |
| 2021-09-30 | $15.24M 10-Q · filed 2021-11-04 |
| 2021-06-30 | $5.48M 10-Q · filed 2021-08-09 |
| 2021-03-31 | $7.06M 10-Q · filed 2021-05-04 |
| 2020-12-31 | $17.55M 10-K · filed 2022-03-07 |
| 2020-09-30 | $36.18M 10-Q · filed 2020-11-04 |
| 2020-06-30 | $14.32M 10-Q · filed 2020-08-10 |
| 2020-03-31 | $50.22M 10-Q · filed 2020-05-06 |
| 2019-12-31 | $54.30M 10-K · filed 2021-02-25 |
| 2019-09-30 | $23.42M 10-Q · filed 2019-11-08 |
| 2019-06-30 | $45.71M 10-Q · filed 2019-08-08 |
| 2019-03-31 | $68.55M 10-Q · filed 2019-05-07 |
| 2018-12-31 | $73.13M 10-K · filed 2020-03-02 |
| 2018-09-30 | $18.62M 10-Q · filed 2018-11-08 |
| 2018-06-30 | $32.73M 10-Q · filed 2018-08-07 |
| 2018-03-31 | $61.88M 10-Q · filed 2018-05-08 |
| 2017-12-31 | $75.90M 10-K · filed 2019-02-28 |
| 2017-09-30 | $999.00K 10-Q · filed 2017-11-07 |
| 2017-06-30 | $13.91M 10-Q · filed 2017-08-10 |
| 2017-03-31 | $20.33M 10-Q · filed 2017-05-12 |
| 2016-12-31 | $0.00 10-K · filed 2018-03-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |